This segment focuses on the development, commercialization, and distribution of the T-SPOT.TB test, a diagnostic tool for detecting latent tuberculosis infection. The T-SPOT.TB test utilizes the company's proprietary T-SPOT technology platform, which measures T-cell responses to specific TB antigens. Research and development efforts are focused on improving test sensitivity and specificity, as well as expanding the test's applications. The test is used in various settings, including hospitals, clinics, and public health institutions, to aid in the diagnosis and management of TB. The T-SPOT.TB test provides a significant advantage over traditional TB tests by offering higher accuracy and the ability to detect latent infections. Future opportunities include expanding the test's market reach and exploring its use in new clinical applications. Regulatory and clinical aspects involve adherence to stringent quality control measures and compliance with relevant guidelines. The segment benefits from partnerships with healthcare providers and public health organizations.

This segment concentrates on the development and commercialization of the T-SPOT.CMV test, an immune monitoring test for cytomegalovirus (CMV). The test quantifies effector T cells that respond to CMV-specific antigens, aiding in the monitoring of CMV-seropositive responses, particularly in transplant recipients. Research and development activities are focused on enhancing the test's accuracy and expanding its applications in various transplant settings. The T-SPOT.CMV test helps clinicians assess the risk of CMV reactivation and guide treatment decisions, improving patient outcomes post-transplantation. The segment's market positioning is strengthened by the growing demand for advanced immune monitoring tools in transplant medicine. Future opportunities include expanding the test's use in other immune-compromised patient populations and developing new CMV-related diagnostic solutions. Regulatory and clinical aspects involve rigorous validation and adherence to clinical guidelines. The segment benefits from collaborations with transplant centers and pharmaceutical companies.